Market overview
The global oncology drugs market is worth USD 294 bn in 2026 and is forecast to reach USD 697 bn by 2036, growing at a 9.0% CAGR. United States is the largest country market and Targeted small molecules is the largest by drug class segment.
| Scope | Anticancer medicines sold worldwide, including targeted therapies, immunotherapies, chemotherapies, hormonal agents, antibody-drug conjugates and supportive oncology drugs. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 270 bn |
| Value 2026 | USD 294 bn |
| Value 2036 | USD 697 bn |
| CAGR 2026-2036 | 9.0% |
| Volume 2026 | 1,603 million packs |
| Volume 2036 | 3,113 million packs |
| Average price 2026 | USD 184 per pack |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Oncology Drugs market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 294 bn |
| 2027 | USD 321 bn |
| 2028 | USD 350 bn |
| 2029 | USD 381 bn |
| 2030 | USD 415 bn |
| 2031 | USD 453 bn |
| 2032 | USD 494 bn |
| 2033 | USD 538 bn |
| 2034 | USD 586 bn |
| 2035 | USD 639 bn |
| 2036 | USD 697 bn |
Oncology Drugs market segmentation
By drug class
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Immunotherapy | 27.0% | 27.4% | USD 79.5 bn | 9.2% |
| Targeted small molecules | 30.0% | 29.1% | USD 88.3 bn | 8.7% |
| Cytotoxic chemotherapy | 9.0% | 4.9% | USD 26.5 bn | 2.7% |
| Hormonal therapy | 9.0% | 6.3% | USD 26.5 bn | 5.2% |
| Antibody-drug conjugates and bispecifics | 10.0% | 20.6% | USD 29.4 bn | 17.2% |
| Supportive care and others | 15.0% | 11.5% | USD 44.1 bn | 6.2% |
By cancer type
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Lung | 16.0% | 16.2% | USD 47.1 bn | 9.2% |
| Breast | 15.0% | 14.5% | USD 44.1 bn | 8.7% |
| Blood cancers | 20.0% | 18.5% | USD 58.9 bn | 8.2% |
| Prostate | 6.0% | 6.1% | USD 17.7 bn | 9.2% |
| Colorectal and GI | 10.0% | 9.7% | USD 29.4 bn | 8.7% |
| Other | 33.0% | 35.0% | USD 97.1 bn | 9.7% |
By modality
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Small molecules | 40.0% | 34.0% | USD 118 bn | 7.2% |
| Monoclonal antibodies | 30.0% | 29.0% | USD 88.3 bn | 8.6% |
| Antibody-drug conjugates and bispecifics | 12.0% | 17.0% | USD 35.3 bn | 12.9% |
| Cell and gene therapies | 7.0% | 10.0% | USD 20.6 bn | 13.0% |
| Hormonal and others | 11.0% | 10.0% | USD 32.4 bn | 8.0% |
By line of therapy
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| First line | 44.0% | 43.0% | USD 129 bn | 8.8% |
| Second line | 30.0% | 30.0% | USD 88.3 bn | 9.0% |
| Later line and maintenance | 26.0% | 27.0% | USD 76.5 bn | 9.4% |
By route
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Oral | 36.0% | 35.0% | USD 106 bn | 8.7% |
| Intravenous | 52.0% | 52.0% | USD 153 bn | 9.0% |
| Subcutaneous and other | 12.0% | 13.0% | USD 35.3 bn | 9.9% |
Top 25 countries for oncology drugs by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 84.0% of 2026 revenue and the 25 countries below together hold 95.5%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 141 bn | 48.0% | USD 340 bn | 9.2% |
| 2 | China | USD 23.5 bn | 8.0% | USD 68.3 bn | 11.2% |
| 3 | Japan | USD 17.7 bn | 6.0% | USD 33.4 bn | 6.6% |
| 4 | Germany | USD 14.7 bn | 5.0% | USD 32.0 bn | 8.1% |
| 5 | France | USD 11.8 bn | 4.0% | USD 24.4 bn | 7.5% |
| 6 | Italy | USD 8.8 bn | 3.0% | USD 18.8 bn | 7.9% |
| 7 | United Kingdom | USD 8.8 bn | 3.0% | USD 19.5 bn | 8.2% |
| 8 | Spain | USD 7.4 bn | 2.5% | USD 15.3 bn | 7.6% |
| 9 | Canada | USD 7.4 bn | 2.5% | USD 16.0 bn | 8.1% |
| 10 | Brazil | USD 5.9 bn | 2.0% | USD 15.3 bn | 10.0% |
| 11 | Australia | USD 5.7 bn | 1.9% | USD 14.8 bn | 10.0% |
| 12 | Netherlands | USD 5.3 bn | 1.8% | USD 12.6 bn | 9.1% |
| 13 | South Korea | USD 4.5 bn | 1.5% | USD 10.7 bn | 9.1% |
| 14 | Switzerland | USD 3.7 bn | 1.3% | USD 8.8 bn | 9.0% |
| 15 | Belgium | USD 3.0 bn | 1.0% | USD 7.2 bn | 9.0% |
| 16 | Turkey | USD 2.5 bn | 0.8% | USD 5.9 bn | 9.1% |
| 17 | Mexico | USD 1.9 bn | 0.6% | USD 4.5 bn | 9.2% |
| 18 | India | USD 1.6 bn | 0.6% | USD 3.8 bn | 9.0% |
| 19 | Poland | USD 1.4 bn | 0.5% | USD 3.3 bn | 9.0% |
| 20 | Sweden | USD 1.1 bn | 0.4% | USD 2.6 bn | 9.0% |
| 21 | Austria | USD 912 mn | 0.3% | USD 2.2 bn | 9.0% |
| 22 | Saudi Arabia | USD 765 mn | 0.3% | USD 1.8 bn | 9.0% |
| 23 | Denmark | USD 589 mn | 0.2% | USD 1.4 bn | 9.0% |
| 24 | Israel | USD 500 mn | 0.2% | USD 1.2 bn | 9.0% |
| 25 | Argentina | USD 412 mn | 0.1% | USD 975 mn | 9.0% |
| Rest of world | USD 13.2 bn | 4.5% | USD 31.8 bn | 9.2% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Merck
- Roche
- Bristol Myers Squibb
- AstraZeneca
- Pfizer
- Novartis
Group 2: Regional and specialist players
- AbbVie
- Johnson and Johnson
- Eli Lilly
- Daiichi Sankyo
- Bayer
- Amgen
- Astellas
- Gilead Sciences
- Regeneron
- Takeda
Group 3: Emerging and niche players
- BeiGene
- Hengrui
- Innovent Biologics
- Zai Lab
- Akeso
- Legend Biotech
- HUTCHMED
- Hansoh Pharmaceutical
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the oncology drugs market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 9.0% is calculated from the resulting values.
The market is divided by drug class, by cancer type, by modality, by line of therapy, by route. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the oncology drugs market?
The global oncology drugs market is estimated at USD 270 bn in 2025 and USD 294 bn in 2026.
How fast will the oncology drugs market grow?
It is forecast to reach USD 697 bn by 2036, a compound annual growth rate of 9.0% from 2026, an increase of USD 402 bn.
Which country is the largest market for oncology drugs?
United States is the largest market by revenue at USD 141 bn in 2026, 48.0% of the global total. The three largest countries together hold 62.0%.
Which country is growing fastest?
Among the ten largest markets, China is growing fastest at 11.2% a year from 2026 to 2036.
Which oncology drugs segment is largest?
In the by drug class split, Targeted small molecules is the largest segment with 30.0% of 2026 revenue.
Who are the leading oncology drugs companies?
Global leaders include Merck, Roche, Bristol Myers Squibb, AstraZeneca.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Monoclonal AntibodiesUSD 273 bn · 6.5% CAGR
- Digital HealthUSD 271 bn · 13.0% CAGR
- Active Pharmaceutical IngredientUSD 245 bn · 6.5% CAGR
- Anti-Neoplastic Pharmaceutical AgentsUSD 239 bn · 9.5% CAGR
- Home HealthcareUSD 410 bn · 8.0% CAGR
- Hospital SuppliesUSD 200 bn · 5.5% CAGR
- Dietary SupplementUSD 198 bn · 7.0% CAGR
- Sterile InjectableUSD 454 bn · 8.5% CAGR
← Oncology Biomarker Translation Services Oncolytic Virus Cancer Therapy →